Literature DB >> 28567588

Immunotherapy and radiation in glioblastoma.

Solmaz Sahebjam1, Andrew Sharabi2, Michael Lim3, Pravin Kesarwani4, Prakash Chinnaiyan5,6.   

Abstract

Radiation therapy plays a central role in the management of glioblastoma. Although primarily thought of as modality to provide local tumor control through DNA damage, the capacity of ionizing radiation to modulate tumor immune response has long been recognized. The recent emergence of clinically active immunotherapies offers exciting potential for harnessing the immune modulatory effects or radiation through combinatorial strategies designed to enhance clinical outcomes. In this Review, we provide background describing the unique immune environment within the central nervous system, how ionizing radiation may modulate the tumor immune response, preclinical and clinical data testing the combination of radiation and immune modulating agents, and highlight some of the current challenges in extending these findings clinically.

Entities:  

Keywords:  Glioblastoma; Immunotherapy; Radiation

Mesh:

Year:  2017        PMID: 28567588     DOI: 10.1007/s11060-017-2413-0

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  58 in total

1.  Identification and localization of the cytokine SDF1 and its receptor, CXC chemokine receptor 4, to regions of necrosis and angiogenesis in human glioblastoma.

Authors:  S A Rempel; S Dudas; S Ge; J A Gutiérrez
Journal:  Clin Cancer Res       Date:  2000-01       Impact factor: 12.531

2.  Cancer; a biological approach. I. The processes of control.

Authors:  M BURNET
Journal:  Br Med J       Date:  1957-04-06

3.  Clinical and Dosimetric Predictors of Acute Severe Lymphopenia During Radiation Therapy and Concurrent Temozolomide for High-Grade Glioma.

Authors:  Jiayi Huang; Todd A DeWees; Shahed N Badiyan; Christina K Speirs; Daniel F Mullen; Sandra Fergus; David D Tran; Gerry Linette; Jian L Campian; Michael R Chicoine; Albert H Kim; Gavin Dunn; Joseph R Simpson; Clifford G Robinson
Journal:  Int J Radiat Oncol Biol Phys       Date:  2015-04-08       Impact factor: 7.038

4.  An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor.

Authors:  Christiane A Opitz; Ulrike M Litzenburger; Felix Sahm; Martina Ott; Isabel Tritschler; Saskia Trump; Theresa Schumacher; Leonie Jestaedt; Dieter Schrenk; Michael Weller; Manfred Jugold; Gilles J Guillemin; Christine L Miller; Christian Lutz; Bernhard Radlwimmer; Irina Lehmann; Andreas von Deimling; Wolfgang Wick; Michael Platten
Journal:  Nature       Date:  2011-10-05       Impact factor: 49.962

5.  Immune-mediated inhibition of metastases after treatment with local radiation and CTLA-4 blockade in a mouse model of breast cancer.

Authors:  Sandra Demaria; Noriko Kawashima; Anne Marie Yang; Mary Louise Devitt; James S Babb; James P Allison; Silvia C Formenti
Journal:  Clin Cancer Res       Date:  2005-01-15       Impact factor: 12.531

6.  Prevention of allogeneic fetal rejection by tryptophan catabolism.

Authors:  D H Munn; M Zhou; J T Attwood; I Bondarev; S J Conway; B Marshall; C Brown; A L Mellor
Journal:  Science       Date:  1998-08-21       Impact factor: 47.728

7.  Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer.

Authors:  Naiyer A Rizvi; Matthew D Hellmann; Alexandra Snyder; Pia Kvistborg; Vladimir Makarov; Jonathan J Havel; William Lee; Jianda Yuan; Phillip Wong; Teresa S Ho; Martin L Miller; Natasha Rekhtman; Andre L Moreira; Fawzia Ibrahim; Cameron Bruggeman; Billel Gasmi; Roberta Zappasodi; Yuka Maeda; Chris Sander; Edward B Garon; Taha Merghoub; Jedd D Wolchok; Ton N Schumacher; Timothy A Chan
Journal:  Science       Date:  2015-03-12       Impact factor: 47.728

8.  HMGB1 is an endogenous immune adjuvant released by necrotic cells.

Authors:  Patrizia Rovere-Querini; Annalisa Capobianco; Paola Scaffidi; Barbara Valentinis; Federica Catalanotti; Marta Giazzon; Ingrid E Dumitriu; Susanne Müller; Matteo Iannacone; Catia Traversari; Marco E Bianchi; Angelo A Manfredi
Journal:  EMBO Rep       Date:  2004-07-23       Impact factor: 8.807

9.  IDO expression in brain tumors increases the recruitment of regulatory T cells and negatively impacts survival.

Authors:  Derek A Wainwright; Irina V Balyasnikova; Alan L Chang; Atique U Ahmed; Kyung-Sub Moon; Brenda Auffinger; Alex L Tobias; Yu Han; Maciej S Lesniak
Journal:  Clin Cancer Res       Date:  2012-08-29       Impact factor: 12.531

10.  Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy.

Authors:  Eric A Reits; James W Hodge; Carla A Herberts; Tom A Groothuis; Mala Chakraborty; Elizabeth K Wansley; Kevin Camphausen; Rosalie M Luiten; Arnold H de Ru; Joost Neijssen; Alexander Griekspoor; Elly Mesman; Frank A Verreck; Hergen Spits; Jeffrey Schlom; Peter van Veelen; Jacques J Neefjes
Journal:  J Exp Med       Date:  2006-04-24       Impact factor: 14.307

View more
  14 in total

Review 1.  Challenges in glioblastoma immunotherapy: mechanisms of resistance and therapeutic approaches to overcome them.

Authors:  Karl John Habashy; Rana Mansour; Charbel Moussalem; Raymond Sawaya; Michel J Massaad
Journal:  Br J Cancer       Date:  2022-06-04       Impact factor: 9.075

Review 2.  Aberrant miRNAs Regulate the Biological Hallmarks of Glioblastoma.

Authors:  Wanli Yu; Sai Liang; Chunzhi Zhang
Journal:  Neuromolecular Med       Date:  2018-09-04       Impact factor: 3.843

3.  Suppressing Dazl modulates tumorigenicity and stemness in human glioblastoma cells.

Authors:  Fengyu Zhang; Ruilai Liu; Haishi Zhang; Cheng Liu; Chunfang Liu; Yuan Lu
Journal:  BMC Cancer       Date:  2020-07-18       Impact factor: 4.430

Review 4.  Harnessing the immune system in glioblastoma.

Authors:  Nicholas F Brown; Thomas J Carter; Diego Ottaviani; Paul Mulholland
Journal:  Br J Cancer       Date:  2018-11-05       Impact factor: 7.640

5.  Mathematical modelling of the synergistic combination of radiotherapy and indoleamine-2,3-dioxygenase (IDO) inhibitory immunotherapy against glioblastoma.

Authors:  Arthur Chakwizira; Jonatan Ahlstedt; Henrietta Nittby Redebrandt; Crister Ceberg
Journal:  Br J Radiol       Date:  2018-05-17       Impact factor: 3.039

6.  Irradiation enhances the therapeutic effect of the oncolytic adenovirus XVir-N-31 in brain tumor initiating cells.

Authors:  Rebecca Czolk; Niklas Schwarz; Henner Koch; Sonja Schötterl; Thomas V Wuttke; Per S Holm; Stephan M Huber; Ulrike Naumann
Journal:  Int J Mol Med       Date:  2019-07-31       Impact factor: 4.101

7.  Selected by gene co-expression network and molecular docking analyses, ENMD-2076 is highly effective in glioblastoma-bearing rats.

Authors:  Sheng Zhong; Yang Bai; Bo Wu; Junliang Ge; Shanshan Jiang; Weihang Li; Xinhui Wang; Junan Ren; Haiyang Xu; Yong Chen; Gang Zhao
Journal:  Aging (Albany NY)       Date:  2019-11-09       Impact factor: 5.682

8.  The Change of Soluble Programmed Cell Death-Ligand 1 in Glioma Patients Receiving Radiotherapy and Its Impact on Clinical Outcomes.

Authors:  Xing-Chen Ding; Liang-Liang Wang; Yu-Fang Zhu; Yan-Dong Li; Shu-Lun Nie; Jia Yang; Hua Liang; Ralph R Weichselbaum; Jin-Ming Yu; Man Hu
Journal:  Front Immunol       Date:  2020-10-30       Impact factor: 7.561

9.  NAMPT overexpression induces cancer stemness and defines a novel tumor signature for glioma prognosis.

Authors:  Antonio Lucena-Cacace; Daniel Otero-Albiol; Manuel P Jiménez-García; Javier Peinado-Serrano; Amancio Carnero
Journal:  Oncotarget       Date:  2017-08-28

Review 10.  Glioblastoma Treatments: An Account of Recent Industrial Developments.

Authors:  Edouard Alphandéry
Journal:  Front Pharmacol       Date:  2018-09-13       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.